SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    O. Ahlehoff, L. Skov, G. Gislason, R. Gniadecki, L. Iversen, L.E. Bryld, S. Lasthein, J. Lindhardsen, S.L. Kristensen, C. Torp-Pedersen, P.R. Hansen, Cardiovascular outcomes and systemic anti-inflammatory drugs in patients with severe psoriasis: 5-year follow-up of a Danish nationwide cohort, Journal of the European Academy of Dermatology and Venereology, 2015, 29, 2
  2. 2
    Olubukola Babalola, Nikita Lakdawala, Bruce E. Strober, Combined biologic therapy for the treatment of psoriasis and psoriatic arthritis: A case report, JAAD Case Reports, 2015, 1, 1, 3

    CrossRef

  3. 3
    Kim Papp, Alice B. Gottlieb, Luigi Naldi, David Pariser, Vincent Ho, Kavitha Goyal, Steven Fakharzadeh, Marc Chevrier, Stephen Calabro, Wayne Langholff, Gerald Krueger, Experience with ustekinumab in patients with psoriasis enrolled in a large, multicenter, prospective, disease-based registry (Psoriasis Longitudinal Assessment and Registry [PSOLAR]), Journal of the American Academy of Dermatology, 2015,

    CrossRef

  4. 4
    Song Liu, Jianan Ren, Jieshou Li, IL-17RA in Intestinal Inflammation, Inflammatory Bowel Diseases, 2015, 21, 1, 154

    CrossRef

  5. 5
    Susanna Mosca, Paola Gargiulo, Nicola Balato, Luisa Di Costanzo, Antonio Parente, Stefania Paolillo, Fabio Ayala, Bruno Trimarco, Filippo Crea, Pasquale Perrone-Filardi, Ischemic cardiovascular involvement in psoriasis: A systematic review, International Journal of Cardiology, 2015, 178, 191

    CrossRef

  6. 6
    K Köck, W J Pan, J M Gow, M J Horner, J P Gibbs, A Colbert, T J Goletz, K J Newhall, W A Rees, Y Sun, Y Zhang, J C O'Neill, A N Umble-Romero, S P Prokop, C D Krill, L Som, S A Buntich, M W Trimble, W H Tsuji, J E Towne, Preclinical development of AMG 139, a human antibody specifically targeting IL-23, British Journal of Pharmacology, 2015, 172, 1
  7. 7
    Caitriona Ryan, Brian Kirby, Psoriasis Is a Systemic Disease with Multiple Cardiovascular and Metabolic Comorbidities, Dermatologic Clinics, 2015, 33, 1, 41

    CrossRef

  8. 8
    J.M. Carrascosa, I. Belinchón, P. de-la-Cueva, R. Izu, J. Luelmo, R. Ruiz-Villaverde, Recomendaciones de expertos para el tratamiento de la psoriasis en situaciones especiales, Actas Dermo-Sifiliográficas, 2015,

    CrossRef

  9. 9
    Onur Boyman, Denis Comte, François Spertini, Adverse reactions to biologic agents and their medical management, Nature Reviews Rheumatology, 2014, 10, 10, 612

    CrossRef

  10. 10
    Gunther Marsche, Michael Holzer, Peter Wolf, Antipsoriatic treatment extends beyond the skin: recovering of high-density lipoprotein function, Experimental Dermatology, 2014, 23, 10
  11. 11
    Sowmya Varada, Suzanne J Tintle, Alice B Gottlieb, Apremilast for the treatment of psoriatic arthritis, Expert Review of Clinical Pharmacology, 2014, 7, 3, 239

    CrossRef

  12. 12
    Erica D. Dommasch, Andrea B. Troxel, Joel M. Gelfand, Counterpoint: A tale of two meta-analyses revisited, Journal of the American Academy of Dermatology, 2014, 70, 2, 381

    CrossRef

  13. 13
    Sarah Churton, Liza Brown, Thuzar M. Shin, Neil J. Korman, Does Treatment of Psoriasis Reduce the Risk of Cardiovascular Disease?, Drugs, 2014, 74, 2, 169

    CrossRef

  14. 14
    Jeremy Hugh, Abby S. Van Voorhees, Rajiv I. Nijhawan, Jerry Bagel, Mark Lebwohl, Andrew Blauvelt, Sylvia Hsu, Jeffrey M. Weinberg, From the Medical Board of the National Psoriasis Foundation: The risk of cardiovascular disease in individuals with psoriasis and the potential impact of current therapies, Journal of the American Academy of Dermatology, 2014, 70, 1, 168

    CrossRef

  15. 15
    Claire Q F Wang, Mayte Suárez-Fariñas, Kristine E Nograles, Claudia A Mimoso, David Shrom, Ernst R Dow, Michael P Heffernan, Robert W Hoffman, James G Krueger, IL-17 Induces Inflammation-Associated Gene Products in Blood Monocytes, and Treatment with Ixekizumab Reduces Their Expression in Psoriasis Patient Blood, Journal of Investigative Dermatology, 2014, 134, 12, 2990

    CrossRef

  16. 16
    Giuseppe Stinco, Cinzia Buligan, Serena Bergamo, Olvino Morgante, Maria Antonietta Iacono, Pasquale Patrone, Myocardial Infarction in a Patient Treated with Anti-Interleukin-12 Biological Agent for Chronic Plaque Psoriasis, Annals of Dermatology, 2014, 26, 1, 137

    CrossRef

  17. 17
    Elisabeth G. Richard, Herbert Hönigsmann, Phototherapy, psoriasis, and the age of biologics, Photodermatology, Photoimmunology & Photomedicine, 2014, 30, 1
  18. 18
    Thrasivoulos Tzellos, Athanassios Kyrgidis, Anastasia Trigoni, Christos C. Zouboulis, Point: Major adverse cardiovascular events and anti-IL 12/23 agents, Journal of the American Academy of Dermatology, 2014, 70, 2, 380

    CrossRef

  19. 19
    Caitriona Ryan, Neil J. Korman, Joel M. Gelfand, Henry W. Lim, Craig A. Elmets, Steven R. Feldman, Alice B. Gottlieb, John Y.M. Koo, Mark Lebwohl, Craig L. Leonardi, Abby S. Van Voorhees, Reva Bhushan, Alan Menter, Research gaps in psoriasis: Opportunities for future studies, Journal of the American Academy of Dermatology, 2014, 70, 1, 146

    CrossRef

  20. 20
    Laura F. Sandoval, Allison Pierce, Steven R. Feldman, Systemic Therapies for Psoriasis: An Evidence-Based Update, American Journal of Clinical Dermatology, 2014, 15, 3, 165

    CrossRef

  21. 21
    Joseph L. Witztum, Andrew H. Lichtman, The Influence of Innate and Adaptive Immune Responses on Atherosclerosis, Annual Review of Pathology: Mechanisms of Disease, 2014, 9, 1, 73

    CrossRef

  22. 22
    Rik J Lories, Kurt de Vlam, Tumour necrosis factor inhibitors in the treatment of psoriatic arthritis: a view on effectiveness, clinical practice and toxicity, Expert Opinion on Biological Therapy, 2014, 14, 12, 1825

    CrossRef

  23. 23
    Alessia Settesoldi, Manuela Coppola, Francesca Rogai, Vito Annese, Ustekinumab: moving the target from psoriasis to Crohn's disease, Expert Review of Gastroenterology & Hepatology, 2014, 8, 1, 5

    CrossRef

  24. 24
    Joshua E Weitz, Christopher T Ritchlin, Ustekinumab: targeting the IL-17 pathway to improve outcomes in psoriatic arthritis, Expert Opinion on Biological Therapy, 2014, 14, 4, 515

    CrossRef

  25. 25
    Andrew H. Lichtman, Christoph J. Binder, Sotirios Tsimikas, Joseph L. Witztum, Adaptive immunity in atherogenesis: new insights and therapeutic approaches, Journal of Clinical Investigation, 2013, 123, 1, 27

    CrossRef

  26. 26
    Bobbak Mansouri, Mahir Patel, Alan Menter, Biological therapies for psoriasis, Expert Opinion on Biological Therapy, 2013, 13, 12, 1715

    CrossRef

  27. 27
    Wolf-Henning Boehncke, Alan Menter, Burden of Disease: Psoriasis and Psoriatic Arthritis, American Journal of Clinical Dermatology, 2013, 14, 5, 377

    CrossRef

  28. 28
    K.A. Papp, C.E.M. Griffiths, K. Gordon, M. Lebwohl, P.O. Szapary, Y. Wasfi, D. Chan, M.-C. Hsu, V. Ho, P.D. Ghislain, B. Strober, K. Reich, Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up, British Journal of Dermatology, 2013, 168, 4
  29. 29
    R.G. Langley, K. Papp, A.B. Gottlieb, G.G. Krueger, K. B. Gordon, D. Williams, J. Valdes, C. Setze, B. Strober, Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open-label extension trial of the interleukin-12/23 monoclonal antibody, briakinumab, in moderate to severe psoriasis, Journal of the European Academy of Dermatology and Venereology, 2013, 27, 10
  30. 30
    Thrasivoulos Tzellos, Athanassios Kyrgidis, Anastasia Trigoni, Christos C. Zouboulis, Association of ustekinumab and briakinumab with major adverse cardiovascular events, Dermato-Endocrinology, 2012, 4, 3, 320

    CrossRef

  31. 31
    L. Puig, Cardiovascular Risk and Psoriasis: the Role of Biologic Therapy, Actas Dermo-Sifiliográficas (English Edition), 2012, 103, 10, 853

    CrossRef

  32. 32
    M.H.A. Rustin, Long-term safety of biologics in the treatment of moderate-to-severe plaque psoriasis: review of current data, British Journal of Dermatology, 2012, 167,
  33. 33
    L. Puig, Riesgo cardiovascular y psoriasis: papel de la terapia biológica, Actas Dermo-Sifiliográficas, 2012, 103, 10, 853

    CrossRef

  34. 34
    M. Goodfield, Sequential use of biologics in moderate-to-severe plaque psoriasis: case studies illustrating an individualized approach, British Journal of Dermatology, 2012, 167,
  35. 35
    Alexander Nast, Phyllis Spuls, Tamar Nijsten, Treatment of Psoriasis,